PRELUDE CORPORATION
Team-building and organizational development workshops
- Sector
- Medtech
- Headquarters
- LAGUNA HILLS, CA
- Latest Form D
- $5M, Nov 2025
- Total capital
- $41.5M
- Federal grants
- $530K
- 1 award · 2015
- Rank in peer group#48 of 95
- Private capital raised
- $40.9M
- 6 Form D · last Nov 2025
- 12 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 25 pending · first 2023
- Rank in peer group#6 of 95
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$5M
- Private capital raisedForm D · SEC · 5th filing$9.3M
- Private capital raisedForm D · SEC · 4th filing$10M
- Private capital raisedForm D · SEC · 3rd filing$9M
- Private capital raisedForm D · SEC · 2nd filing$5.5M
- Private capital raisedForm D · SEC · 1st filing$2.2M
- Federal grantHealth and Human S · Phase II · Multi-marker prognostic profile to predict invasive progression in DCIS patients$530K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
7months
from PRELUDE CORPORATION’s first federal award to its first private round.
- First federal award · Aug 2015
- Health and Human S · $530K
- First Form D · Mar 2016
- $2.2M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 95 peers
Line = medianMedtech · Instrument
- Federal grants#48 · top 51%
- Granted patents#6 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alejandro B. SanchezDirectorNamed in SEC Form D filings
- ANDREW J. WADEExecutive OfficerNamed in SEC Form D filings
- DANIEL J. FORCHEExecutive Officer, DirectorNamed in SEC Form D filings
- Derek B. MaetzoldDirectorNamed in SEC Form D filings
- Gerrit B. AdamsDirectorNamed in SEC Form D filings
- HUGH J. NEUHARTHDirectorNamed in SEC Form D filings
Show all 8 people
- Olav B. BergheimExecutive Officer, DirectorNamed in SEC Form D filings
- WILLIAM J. LINKDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 28- PendingDcis Recurrence And Invasive Breast CancerUSPTOApplication 19387345
- GrantedDcis Recurrence And Invasive Breast CancerUSPTOUS 12,487,242
- PendingIdentification And Methods Of Treatment Of Breast CancerUSPTOApplication 18998333
Show all 28 patent records
- Dcis Recurrence And Invasive Breast CancerMar 12, 2026 · Application 19387345Pending
- Dcis Recurrence And Invasive Breast CancerDec 2, 2025 · US 12,487,242Granted
- Identification And Methods Of Treatment Of Breast CancerAug 28, 2025 · Application 18998333Pending
- Methods For Treating A Subject With Local Invasive Breast Cancer Based On Pdgfrb LevelsDec 7, 2023 · Application 18033054Pending
- PD-1 As A Predictive Marker For Therapy In CancerNov 23, 2023 · Application 17998334Pending
- Method Of Selection For Treatment Of Subjects At Risk Of Invasive Breast CancerNov 21, 2023 · US 11,821,900Granted
- Dcis Recurrence And Invasive Breast CancerJan 3, 2023 · US 11,543,411Granted
- PD-L1 As A Predictive Marker For Therapy In CancerOct 27, 2022 · Application 17657537Pending
- Method Of Selection For Treatment Of Subjects At Risk Of Invasive Breast CancerJun 16, 2022 · Application 17275406Pending
- Biosignature Integrating Immune And Metabolic Signaling Axes To Assess Limited Radiation Therapy Response In Early Stage Breast Cancer From A Low Risk CohortApplication 63484966Pending
- Identification And Methods Of Treatment Of Breast CancerApplication 63479049Pending
- Identification And Methods Of Treatment Of Breast CancerApplication 63477078Pending
- Identification And Methods Of Treatment Of Breast CancerApplication 63369500Pending
- PD-L1 As A Predictive Marker For Therapy In CancerApplication PCTUS2022022934Pending
- PD-1 As A Predictive Marker For Therapy In CancerApplication PCTUS2021032080Pending
- PD-1 As A Predictive Marker For Therapy In CancerApplication 63169532Pending
- PD-L1 As A Predictive Marker For Therapy In CancerApplication 63169517Pending
- Method Of Selection For Treatment Of Subjects At Risk Of Invasive Breast CancerApplication PCTUS2019051128Pending
- Method Of Treating Breast Cancer Using A Breast Cancer Panel Involving CD8, FOXP3, And/or PD-1 MarkersApplication 19584981Pending
- Biosignatures For Breast Cancer Treatment And Methods Of Use ThereofApplication 19622560Pending
- Biosignature Integration To Assess Therapy Response In Breast CancerApplication 19153516Pending
- Biosignatures For Breast Cancer Treatment And Methods Of Use TherofApplication PCTUS2025019235Pending
- Method Of Treating Breast Cancer Using A Breast Cancer Panel Involving CD8, FOXP3, And/or PD-1 MarkersApplication PCTUS2024054797Pending
- Multi-omic BiosignatureApplication 63564411Pending
- Biosignature Integration To Assess Therapy Response In Breast CancerApplication PCTUS2024015652Pending
- Method Of Treating Breast Cancer Using A Breast Cancer Panel Involving CD8, FOXP3, And PD1 MarkersApplication 63596937Pending
- Identification And Methods Of Treatment Of Breast CancerApplication PCTUS2023070978Pending
- Identification And Methods Of Treatment Of Breast CancerApplication 63496608Pending
Related companies, and why
- NEUROGAMI MEDICAL, INC.Similar federal contract value in Medtech · null in contracts
- SEQUENT MEDICAL, INC.Similar federal contract value in Medtech · null in contracts
- GP IONICS LLCSimilar federal contract value in Medtech · null in contracts
- EIT USA, INC.Similar federal contract value in Medtech · null in contracts
- Third Pole, Inc.Similar federal contract value in Medtech · null in contracts
- SEABIRD LIFESCIENCES LLCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .